
Scott Aaronson, MD
Chief Science Officer
Sheppard Pratt

Accelerated Neuromodulation in the Treatment of Depression
Thursday, February 11, 2027
8:00 AM - 9:00 AM
Use of Psychedelics in Severely Treatment Resistant Depression
Thursday, February 11, 2027
9:00 AM - 10:00 AM
Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves on the board of the American Society of Clinical Psychopharmacology.
He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital. Dr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. He is the Director of the Sheppard Pratt Centre of Excellence focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness. He has completed several supported investigator initiated studies to determine the safety and efficacy of psilocybin in severely treatment resistant depression (>4 failures in the current episode), bipolar type 2 depression and treatment resistant depression with chronic, active suicidal ideation. He is the editor for the APA book—Psychedelics: Transforming Psychiatry.
Lecture One Summary:
This presentation will review the emerging role of psychedelic therapies in the treatment of psychiatric disorders, with a focus on conditions where current treatment options may be limited. The session will examine the evidence supporting psychedelic-assisted treatment for conditions such as chronic suicidal ideation and post-traumatic stress disorder, while also addressing patient populations at greater risk for adverse events. The presentation will further explore key considerations for treatment setting, patient selection, and the clinical environment needed to support the safe and effective use of psychedelic therapies.
Lecture Two Summary:
This presentation will review the role of transcranial magnetic stimulation (TMS) in the treatment of major depressive disorder, particularly for patients who have not responded to multiple medication trials. The session will compare standard TMS treatment approaches with newer accelerated protocols designed to reduce the overall treatment time from several weeks to as little as one day to one week. The presentation will also examine the use of neuronavigation in TMS and how it may help refine treatment targeting and potentially improve clinical outcomes.
Lecture One Goals and Learning Objectives:
-
Identify the target psychiatric illnesses with the best evidence base for improvement from psychedelic therapy.
-
Recognize the patients at highest risk for adverse events from the use of psychedelics.
-
Describe the model treatment environment for psychedelic therapy.
Lecture Two Goals and Learning Objectives:
-
Identify the target population for TMS.
-
Describe the typical treatment protocols for standard TMS vs. accelerated TMS
-
Recognize where neuronavigatuion fits in the TMS paradigm.
Disclosures:
Grant/Research Support : Compass Pathways (past)
Consultant : Neuronetics, LivaNova, AbbVie
Royalty : APPI
.png)